Results 151 to 160 of about 9,288,830 (350)

Lack of Estrogen Receptor Associated with an Increased Response Rate to Cytotoxic Chemotherapy in Metastatic Breast Cancer?

open access: yes, 1980
Recent advances in the management of metastatic breast cancer have led to a significant improvement in patient care. A variety of new kinds of endocrine therapy, such as antiestrogen administration or medical adrenalectomy with aminoglutethimide, have ...
Allegra, J. C   +3 more
core   +1 more source

Hemoglobin is associated with BMDs and risk of the 10-year probability of fractures in patients with type 2 diabetes mellitus

open access: yesFrontiers in Endocrinology
PurposeThis study aimed to investigate the associations between hemoglobin (HGB) levels and bone mineral density (BMD) and fracture risk in type 2 diabetes mellitus(T2DM) population of different ages.
Ren-xuan Li   +73 more
doaj   +1 more source

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

open access: yesMolecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault   +12 more
wiley   +1 more source

Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study

open access: yes, 2007
Little is known about patients’ experience of, and knowledge about adjuvant endocrine therapy. A European survey was carried out to explore this knowledge gap. The 547 post-menopausal women with early breast cancer, from 9 European countries, completed a
Georgiou, V   +19 more
core   +1 more source

Research progress of resistance to aromatase inhibitor therapy in breast cancer

open access: yesZhongguo aizheng zazhi, 2021
Breast cancer is one of the most common malignancies in women. About 70% of patients are estrogen receptor (ER) and/or progesterone receptor (PR) positive.
李芷君, 徐兵河
doaj  

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim   +17 more
wiley   +1 more source

EDC-2 : The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals

open access: yes, 2015
The Endocrine Society's first Scientific Statement in 2009 provided a wake-up call to the scientific community about how environmental endocrine-disrupting chemicals (EDCs) affect health and disease.
Prins, Gail S.,   +7 more
core   +1 more source

Endocrine therapy and COVID-19 outcomes in women with breast cancer: a nationwide register- based matched cohort study

open access: yesBMC Cancer
Purpose The COVID-19 pandemic posed substantial challenges to cancer care, raising concerns about the safety of ongoing endocrine therapy in women with breast cancer.
Aglaia Schiza   +4 more
doaj   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

open access: yesMolecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir   +9 more
wiley   +1 more source

Immune potentiating effects of the HDAC inhibitor Zabadinostat on human immune and tumor cells

open access: yesMolecular Oncology, EarlyView.
Zabadinostat (CXD101) is a second‐generation class I histone deacetylase inhibitor (HDACi). We show that Zabadinostat activates human T cells and natural killer cells while reducing frequencies and function of regulatory T cells. Zabadinostat also increases T cell stemness and modulates tumor cell phenotype to potentially enhance immune recognition ...
Stephanie C. Pitts   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy